<DOC>
	<DOCNO>NCT01559025</DOCNO>
	<brief_summary>The primary objective study evaluate action DPP-IV inhibitor prevention progressive beta cell dysfunction patient type 1 diabetes mellitus newly diagnosis ( le 6 month ) . The secondary objective : 1 . To define immune inflammatory profile 2 . To define secretion glucagon GLP-1 3 . To assess glycemic variability</brief_summary>
	<brief_title>Evaluation Vildagliptin ( Galvus® ) add-on Insulin New-onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Clinical autopsy study show 30 % patient type 1 diabetes mellitus show detectable β-cell function clinical diabetes . The preservation endogenous insulin production , even small , great impact evolution long-term disease improve glycemic control , reduce chronic diabetes complication hypoglycemia . Strategies prevent loss beta cell base stop autoimmune process also preservation regeneration beta cell . Currently question potential use GLP-1 new-onset type 1 diabetes . The justification issue base fact class drug , besides act insulin secretion glucose regulation , may effective preserve expand beta cell mass , show animal . Ideal candidate treatment newly diagnose patient still significant viable beta cell mass .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Aged 18 35 year Up 6 month clinical diagnosis Fasting Cpeptide ≥ 0.25 ng / ml HbA1C &lt; 9.0 % Positive autoantibody ( antiGAD , AntiInsulin AntiIA2 ) Without chronic complication Hepatic , cardiac , pulmonary hematologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Galvus</keyword>
</DOC>